Overview
This category page covers biotechnology and pharmaceutical companies developing [NRF2 activators](/mechanisms/nrf2-parkinsons-disease), [KEAP1 inhibitors](/genes/keap1), and antioxidant response modulators specifically for Parkinson's disease. The [Nrf2-KEAP1 pathway](/mechanisms/nrf2-keap1-pathway) is the primary cellular defense mechanism against oxidative stress, which is a central pathological feature of PD. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection of dopaminergic neurons.
This page complements the broader [AD Nrf2-Keap1 Pathway Companies page](/companies/ad-nrf2-keap1-oxidative-stress-therapy-companies) with a specific focus on Parkinson's disease programs.
Pathway / Mechanism Diagram
graph TD
A["Normal Conditions"] --> B["Keap1 Binds NRF2"]
B --> C["NRF2 Ubiquitination"]
C --> D["Proteasomal Degradation"]
E["Oxidative Stress"] --> F["Keap1 Cysteine Modification"]
F --> G["NRF2 Release"]
G --> H["Nuclear Translocation"]
H --> I["ARE Binding"]
I --> J["HO-1: Heme Detoxification"]
I --> K["NQO1: Quinone Detoxification"]
I --> L["GST: Glutathione Conjugation"]
I --> M["Catalase, SOD"]
J --> N["Neuroprotection"]
K --> N
L --> N
M --> N
O["NRF2 Decline in Aging"] --> P["Reduced Antioxidant Defense"]
P --> Q["Oxidative Neurodegeneration"]
style N fill:#1b5e20,color:#e0e0e0
style Q fill:#ef5350,color:#e0e0e0
style H fill:#006494,color:#e0e0e0
...Overview
This category page covers biotechnology and pharmaceutical companies developing [NRF2 activators](/mechanisms/nrf2-parkinsons-disease), [KEAP1 inhibitors](/genes/keap1), and antioxidant response modulators specifically for Parkinson's disease. The [Nrf2-KEAP1 pathway](/mechanisms/nrf2-keap1-pathway) is the primary cellular defense mechanism against oxidative stress, which is a central pathological feature of PD. Activation of Nrf2 leads to upregulation of antioxidant genes, enhancement of mitochondrial function, suppression of neuroinflammation, and protection of dopaminergic neurons.
This page complements the broader [AD Nrf2-Keap1 Pathway Companies page](/companies/ad-nrf2-keap1-oxidative-stress-therapy-companies) with a specific focus on Parkinson's disease programs.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Key Therapeutic Rationale
The Nrf2 pathway is particularly relevant for Parkinson's disease because:
Dopaminergic neuron vulnerability: Substantia nigra pars compacta neurons face exceptionally high oxidative stress from [dopamine](/mechanisms/dopamine-metabolism) metabolism and mitochondrial respiration
Documented pathway dysfunction: Post-mortem studies show reduced Nrf2 nuclear translocation and target gene expression (NQO1, HMOX1, GCLC) in PD substantia nigra[@last2022]
Multifactorial protection: Nrf2 activation simultaneously addresses oxidative stress, mitochondrial dysfunction, neuroinflammation, and protein aggregation
Disease-modifying potential: Unlike dopaminergic therapies that only manage symptoms, Nrf2 activation targets upstream disease mechanismsKey Therapeutic Approaches
| Approach | Description | Companies |
|----------|-------------|-----------|
| Direct Nrf2 Activators | Covalent or non-covalent KEAP1 binders that release Nrf2 | Evgen Pharma, Biogen |
| Keap1 Inhibitors | Disrupt Keap1-Nrf2 binding interface | Nacuity, Evotec |
| Sulforaphane Derivatives | Natural product-based Nrf2 activators with optimized formulations | Evgen Pharma |
| ARE Modulators | Direct modulation of antioxidant response element transcription | Various research-stage |
| Gene Therapy | AAV-mediated NFE2L2 delivery to substantia nigra | Research-stage |
Nrf2 Activator Companies
Evgen Pharma — SFX-01 (Sulforaphane)
Evgen Pharma is the most advanced company with a dedicated Parkinson's disease program for Nrf2 activation.
- Lead Candidate: [SFX-01](/companies/evgen-pharma), a proprietary stabilized formulation of sulforaphane
- Mechanism: Sulforaphane is a potent electrophilic Nrf2 activator that reacts with KEAP1 cysteine residues, releasing Nrf2 and triggering ARE-driven gene expression
- Target Genes: HO-1, NQO1, GCLC, GCLM, GST family — all upregulated by Nrf2 activation
- Indication: [Parkinson's disease](/diseases/parkinsons-disease) — Phase 1/2
- Clinical Rationale: Preclinical MPTP model data showed protection of dopaminergic neurons with increased NQO1 and HO-1 expression in substantia nigra
- Program Status: Phase 1/2 clinical trial application submitted
[Evgen Pharma company page](/companies/evgen-pharma)
Biogen — Dimethyl Fumarate
Biogen has explored repurposing dimethyl fumarate (Tecfidera), already approved for multiple sclerosis, for Parkinson's disease.
- Lead Candidate: [Dimethyl fumarate](/therapeutics/dimethyl-fumarate) (Tecfidera)
- Mechanism: Nrf2 activator through KEAP1 cysteine modification; also immunomodulatory via HCA2 receptor
- Indication: Parkinson's disease — Phase 2
- PD Trial: NCT03425656 — completed[@bahn2019]
- Results: Showed favorable safety profile; efficacy signals were modest, informing future trial designs
- Dual Mechanism: Beyond Nrf2 activation, DMF modulates gut immune axis and suppresses neuroinflammation
[Biogen company page](/companies/biogen)
Reata Pharmaceuticals (now Alnylam) — Bardoxolone Methyl
Reata Pharmaceuticals (acquired by Alnylam in 2023) developed bardoxolone methyl, one of the most potent direct Nrf2 activators.
- Lead Candidate: Bardoxolone methyl (CDDO-Me)
- Mechanism: Semi-synthetic triterpenoid; IC50 ~1 nM for Nrf2 activation. Covalently modifies KEAP1 cysteine residues with high potency
- Indication: Parkinson's disease (with diabetes comorbidity) — Phase 1/2 completed
- PD Rationale: Protected dopaminergic neurons in rotenone models; improved mitochondrial function in patient-derived iPSCs
- Note: Alnylam acquired Reata primarily for the Friedreich's ataxia program (omaveloxolone). PD program status under evaluation
[Alnylam company page](/companies/alnylam)
Research-Stage and Preclinical Programs
Nacuity Pharmaceuticals — NPI-001
Nacuity Pharmaceuticals is an Australian biotech with a selective Nrf2 activator in preclinical development for Alzheimer's disease, with potential extension to PD:
- Lead Candidate: NPI-001 (non-covalent Keap1-Nrf2 interface binder)
- Mechanism: High selectivity for Nrf2 pathway with minimal off-target kinase activity
- Indication: Alzheimer's disease (primary), Parkinson's disease (potential extension)
- Stage: Preclinical (IND-enabling for AD)
- Note: While AD is the primary indication, the oxidative stress rationale is directly applicable to PD
[Nacuity Pharmaceuticals company page](/companies/nacuity-pharmaceuticals)
Academia-Spinout Programs
Multiple academic groups have Nrf2-NPD programs in various stages:
| Organization | Program | Stage | Notes |
|--------------|---------|-------|-------|
| Keapstone Therapeutics (U. Edinburgh) | Keap1-Nrf2 modulators | Preclinical | Spinout from Nrf2 biology research |
| Evotec | High-throughput Keap1 screening | Discovery | Partnered with pharma on CNS Nrf2 programs |
| University of Pittsburgh | AAV-NFE2L2 gene therapy | Preclinical | Direct substantia nigra injection in models |
| Scripps/UC Irvine | Novel Nrf2 activators | Preclinical | Non-electrophilic scaffold identification |
Pipeline Overview
| Company | Drug/Program | Mechanism | PD Stage | Notes |
|---------|--------------|-----------|----------|-------|
| Evgen Pharma | SFX-01 | Sulforaphane Nrf2 activator | Phase 1/2 | Oral, stabilized formulation |
| Biogen | Dimethyl fumarate | Nrf2 activator + HCA2 | Phase 2 (completed) | Repurposed MS drug |
| Alnylam (Reata) | Bardoxolone methyl | Direct Nrf2 activator | Phase 1/2 (completed) | Acquired 2023 |
| Nacuity Pharma | NPI-001 | Selective Nrf2 activator | Preclinical AD | Potential PD extension |
| Evotec | Keap1 inhibitors | Keap1-Nrf2 disruptors | Discovery | Pharma partnerships |
| University groups | AAV-NFE2L2 | Gene therapy | Preclinical | Research-stage |
Clinical Trial Landscape
Active/Recent PD Nrf2 Trials
| Trial ID | Drug | Phase | Status | Key Endpoints |
|----------|------|-------|--------|---------------|
| NCT03425656 | Dimethyl fumarate | Phase 2 | Completed | MDS-UPDRS, safety |
| NCT04477210 | Sulforaphane | Phase 1 | Completed | Safety, CSF biomarkers |
| — | SFX-01 (Evgen) | Phase 1/2 | Planned | Motor scores, oxidative stress biomarkers |
| — | Bardoxolone methyl | Phase 1/2 | Completed | Safety, mitochondrial function |
Biomarkers for Nrf2 Activation in PD
Key biomarkers used to demonstrate target engagement:
- NQO1 activity: Peripheral blood mononuclear cells — correlates with Nrf2 activation
- HO-1 levels: CSF and blood — Nrf2 target gene product
- 8-OHdG: Urinary and CSF — marker of oxidative DNA damage
- Glutathione (GSH): CSF — Nrf2-regulated antioxidant
- p62/SQSTM1: Blood and CSF — autophagy-Nrf2 feedback marker
Mechanism of Action in PD
Nrf2 Activation Cascade in Parkinson's Disease
The Nrf2-KEAP1 pathway operates through the following cascade in PD:
Under normal conditions: Nrf2 is bound by KEAP1 in the cytoplasm, targeted for ubiquitin-proteasome degradation
Oxidative stress (ROS from dopamine oxidation, mitochondria, microglia): Oxidizes KEAP1 cysteine residues (C151, C273, C288)
Conformational change: KEAP1 releases Nrf2
Nuclear translocation: Stabilized Nrf2 moves to the nucleus
ARE binding: Nrf2 binds Antioxidant Response Elements in promoter regions
Gene upregulation:
- Antioxidant enzymes: HO-1, NQO1, SOD1, SOD2, catalase, GPX
- Glutathione synthesis: GCLC (catalytic), GCLM (regulatory)
- Detoxification: GST family, UGT1A1
- Mitochondrial biogenesis: PGC-1alpha via NRF-1
- Proteostasis: p62, proteasome subunits
Neuroprotective Outcomes
| Nrf2 Target | Neuroprotective Effect in PD |
|-------------|------------------------------|
| HO-1 | Degrades pro-oxidant heme; generates biliverdin/bilirubin antioxidants |
| NQO1 | Prevents redox cycling of quinones from dopamine oxidation |
| GCLC/GCLM | Increases glutathione synthesis — primary neuronal antioxidant |
| PGC-1alpha | Mitochondrial biogenesis; counters Complex I deficiency |
| p62 | Autophagy activation; clears alpha-synuclein aggregates |
| Hsp70 | Chaperone protection against proteotoxic stress |
Cross-Links
NeuroWiki Mechanism Pages
- [Nrf2 Signaling in Parkinson's Disease](/mechanisms/nrf2-parkinsons-disease) — Primary mechanism page
- [NRF2-KEAP1 Oxidative Stress Response Pathway](/mechanisms/nrf2-keap1-pathway) — Broader pathway
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration) — Disease context
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons) — Mitochondrial connection
- [Neuroinflammation in AD, PD, ALS](/mechanisms/neuroinflammation-ad-pd-als) — Inflammation connection
NeuroWiki Company Pages
- [Evgen Pharma](/companies/evgen-pharma) — SFX-01 for PD
- [Nacuity Pharmaceuticals](/companies/nacuity-pharmaceuticals) — NPI-001 Nrf2 activator
- [Alzheimer's Disease Nrf2-Keap1 Therapy Companies](/companies/ad-nrf2-keap1-oxidative-stress-therapy-companies) — AD companion page
NeuroWiki Gene/Protein Pages
- [NFE2L2 (Nrf2) Gene](/genes/nfe2l2) — Drug target
- [KEAP1 Gene](/genes/keap1) — Drug target (upstream)
- [NQO1 Protein](/proteins/nqo1-protein) — Nrf2 target gene
- [HMOX1 (HO-1) Protein](/proteins/hmox1-protein) — Nrf2 target gene
- [PGC-1alpha (PPARGC1A) Protein](/proteins/pgc1-alpha) — Nrf2-regulated mitochondrial master regulator
NeuroWiki Therapeutic Pages
- [Sulforaphane Neuroprotection](/therapeutics/sulforaphane-neuroprotection) — Natural Nrf2 activator
- [Dimethyl Fumarate](/therapeutics/dimethyl-fumarate) — Repurposed Nrf2 activator
References
[Last et al., Nrf2 activators in Parkinson's disease clinical trials — Movement Disorders (2022)](https://doi.org/10.1002/mds.28964)
[Cuadrado et al., Nrf2 as a therapeutic target for neurodegenerative diseases — Nature Reviews Drug Discovery (2022)](https://doi.org/10.1038/s41573-022-00495-3)
[Bahn et al., Dimethyl fumarate in Parkinson's disease — Parkinsonism and Related Disorders (2019)](https://doi.org/10.1016/j.parkreldis.2019.03.014)
[Nrf2 Signaling in Parkinson's Disease — NeuroWiki Mechanism Page](/mechanisms/nrf2-parkinsons-disease)